Modalities and future prospects of gene therapy in heart transplantation

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 6, 2009, Pages 1036-1044

  Vassalli, Giuseppe ^a,b,c   Roehrich, Marc Estienne ^b   Vogt, Pierre ^b   Pedrazzini, Giovanni B ^a   Siclari, Francesco ^a   Moccetti, Tiziano ^a   von Segesser, Ludwig K ^b  

^a DIVISION OF CARDIOLOGY   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Gene therapy; Graft vasculopathy; Heart transplantation; Rejection; Tolerance

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; FAS LIGAND; GELATINASE A; HEME OXYGENASE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; PROTEIN BCL X; TISSUE PLASMINOGEN ACTIVATOR;

DENDRITIC CELL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; T LYMPHOCYTE;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 67349235533     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.01.044     Document Type: Review

References (75)

1. Weiss E.S., Nwakanma L.U., Patel N.D., and Yuh D.D. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. J Heart Lung Transplant 27 (2008) 184-191
2. Vassalli G., Büeler H., Dudler J., von Seegsser L.K., and Kappenberger L. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol 90 (2003) 229-238
3. Le Bas-Bernardet S., Anegon I., and Blancho G. Progress and prospects: genetic engineering in xenotransplantation. Gene Ther 15 (2008) 1247-1256
4. Fleury S., Driscoll R.A., Simeoni E., Dudler J., von Segesser L.K., Kappenberger L., and Vassalli G. Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors. Basic Res Cardiol 99 (2004) 247-256
5. Müller O.J., Leuchs B., Pleger S.T., Grimm D., Franz W.M., Katus H.A., and Kleinschmidt J.A. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 70 (2006) 70-78
6. Miyagi N., Rao V.P., Ricci D., Du Z., Byrne G.W., Bailey K.R., Nakai H., Russell S.J., and McGregor C.G. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart Lung Transplant 27 (2008) 554-560
7. Fleury S., Simeoni E., Zuppinger C., Déglon N., von Segesser L.K., Kappenberger L., and Vassalli G. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation 107 (2003) 2375-2382
8. Cefaï D., Simeoni E., Ludunge K.M., Driscoll R., von Segesser L.K., Kappenberger L., and Vassalli G. Multiply attenuated, self-inactivating lentiviral vectors efficiently transduce human coronary artery cells in vitro and rat arteries in vivo. J Mol Cell Cardiol 38 (2005) 333-344
9. Vassalli G., Simeoni E., Li J., and Fleury S. Lentiviral gene transfer of the chemokine antagonist RANTES 9-68 prolongs heart graft survival. Transplantation 81 (2006) 240-246
10. Chan S.Y., Goodman R.E., Szmuszkovicz J.R., Roessler B., Eichwald E.J., and Bishop D.K. DNA-liposome versus adenoviral mediated gene transfer of transforming growth factor beta1 in vascularized cardiac allografts: differential sensitivity of CD4+ and CD8+ T cells to transforming growth factor beta1. Transplantation 70 (2000) 1292-1304
11. Hong Y.S., Laks H., Cui G., Chong T., and Sen L. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 21 (2002) 1188-1200
12. Tashiro H., Aoki M., Isobe M., Hashiya N., Makino H., Kaneda Y., Ogihara T., and Morishita R. Development of novel method of non-viral efficient gene transfer into neonatal cardiac myocytes. J Mol Cell Cardiol 39 (2005) 503-509
13. Akita H., and Harashima G. Advances in non-viral gene delivery: using multifunctional envelope-type nano-devices. Expert Opin Drug Deliv 5 (2008) 847-859
14. Poston R.S., Mann M.J., Hoyt E.G., Ennen M., Dzau V.J., and Robbins R.C. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. Transplantation 68 (1999) 825-832
15. Iwata A., Sai S., Nitta Y., Chen M., deFries-Hallstrand R., Dalesandro J., Thomas R., and Allen M.D. Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation 103 (2001) 2753-2759
16. Abunasra H.J., Smolenski R.T., Yap J., Sheppard M., O'Brien T., and Yacoub M.H. Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation. J Thorac Cardiovasc Surg 125 (2003) 998-1006
17. Abraham N.G., and Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60 (2008) 79-127 Erratum in: Pharmacol Rev 2008;60:242
18. Braudeau C., Bouchet D., Tesson L., Iver S., Rémy S., Buelow R., Anegon I., and Chaveau C. Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. Gene Ther 11 (2004) 701-719
19. Suzuki K., Murtuza B., Smolenski R.T., Sammut I.A., Suzuki N., Kaneda Y., and Yacoub M.H. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104 Suppl. 1 (2001) I308-I313
20. Simeoni E., Dudler J., Fleury S., Li J., Pagnotta M., Pascual M., von Segesser L.K., and Vassalli G. Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. Eur J Cardiothorac Surg 31 (2007) 222-228
21. Ritter T., Schroder G., Risch K., Vergopoulos A., Shean M.K., Kolls J., Brock J., Lehmann M., and Volk H.D. Ischemia/reperfusion injury-mediated down-regulation of adenovirus-mediated gene expression in a rat heart transplantation model is inhibited by co-application of a TNFRp55-Ig chimeric construct. Gene Ther 7 (2000) 1238-1243
22. Li J., Simeoni E., Fleury S., Dudler J., Fiorini E., Kappenberger L., von Segesser L.K., and Vassalli G. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg 29 (2006) 779-783
23. Dudler J., Simeoni E., Fleury S., Li J., Pagnotta M., Pascual M., von Segesser L.K., and Vassalli G. Gene transfer of IL-18 binding protein attenuates cardiac allograft rejection. Transplant Int 20 (2007) 460-466
24. Sakaguchi T., Sawa Y., Fukushima N., Nishimura M., Ichikawa H., Kaneda Y., and Matsuda H. A novel strategy of decoy transfection against nuclear factor-kappaB in myocardial preservation. Ann Thorac Surg 71 (2001) 629-630
25. Brauner R., Nonoyama M., Laks H., Drinkwater Jr. S.C., McCaffery S., Drake T., Berk A.J., Sen L., and Wu L. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg 114 (1997) 923-933
26. David A., Chetritt J., Guillot C., Tesson L., Heslan J.M., Cuturi M.C., Soulillou J.P., and Anegon I. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther 7 (2000) 505-510
27. Ke B., Ritter T., Kato H., Zhai Y., Li J., Lehmann M., Busuttil R.W., Volk H.D., and Kupiec-Weglinski J.W. Regulatory cells potentiate the efficacy of IL-4 gene transfer by up-regulating Th2-dependent expression of protective molecules in the infectious tolerance pathway in transplant recipients. J Immunol 164 (2000) 5739-5745
28. Ke B., Shen X.D., Zhai Y., Gao F., Busuttil R.W., Volk H.D., and Kupiec-Weglinski J.W. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 13 (2002) 1845-1857
29. Furukawa H., Oshima K., Tung T., Cui G., Laks H., and Sen L. Liposome-mediated combinatorial cytokine gene therapy induces localized synergistic immunosuppression and promotes long-term survival of cardiac allografts. J Immunol 174 (2005) 6983-6992
30. Smith R.N., Ueno T., Ito T., Tanaka K., Shea S.P., and Abdi R. Chemokines and chronic heart allograft rejection. Transplantation 84 (2007) 442-444
31. Abdi R., Means T.K., Ito T., Smith R.N., Najafian N., Jurewicz M., Tchipachvili V., Charo I., Auchincloss Jr. H., Sayegh M.H., and Luster A.D. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol 172 (2004) 767-775
32. DeBruyne L.A., Li K., Bishop D.K., and Bromberg J.S. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther 7 (2000) 575-582
33. Sayegh M.H., and Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338 (1998) 1813-1821
34. Guillot C., Mathieu P., Coathalem H., LeMauff B., Castro M.G., Tesson L., Usal C., Laumonier T., Brouard S., Soulillou J.P., Löwenstein P.R., Cuturi M.C., and Anegon I. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol 164 (2000) 5258-5268
35. Guillot C., Guillonneau C., Mathieu P., Gerder C.A., Ménoret S., Braudeau C., Tesson L., Renaudin K., Castro M.G., Löwenstein P.R., and Anegon I. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 168 (2002) 1600-1609
36. Yamashita K., Masunaga T., Yanagida N., Takehara M., Hashimoto T., Kobayashi T., Echizenya H., Hua N., Fujita M., Murakami M., Furukawa H., Uede T., and Todo S. Long-term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapies. Transplantation 76 (2003) 1089-1096
37. Guillonneau C., Hill M., Hubert F.X., Chiffoleau E., Hervé C., Li X.L., Heslan M., Usal C., Tesson L., Ménoret S., Saoudi A., LeMauff B., Josien R., Cuturi M.C., and Anegon I. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 117 (2007) 871-873
38. Li J., Meinhardt A., Roehrich M.E., Golshayan D., Dudler J., Pagnotta M., Trucco M., and Vassalli G. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Circ Physiol 293 (2007) H3415-H3423
39. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., and Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (2000) 1027-1034
40. Dudler J., Li J., Pagnotta M., von Segesser L.K., and Vassalli G. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 82 (2006) 1733-1737
41. Bagley J., and Jacomini J. Gene therapy in organ transplantation. Gene Ther 10 (2003) 605-611
42. Madsen J.C., Superina R.A., Wood K.J., and Morris P.J. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 331 (1988) 161-164
43. Wong W., Stranford S.A., Morris P.J., and Wood K.J. Retroviral gene transfer of a class I MHC gene to recipient bone marrow induces tolerance to alloantigens in vivo. Transplant Proc 29 (1997) 1130
44. Fry J.W., Morris P.J., and Wood K.J. Adenoviral transfer of a single donor-specific MHC class I gene to recipient bone marrow cells can induce specific immunological unresponsiveness in vivo. Gene Ther 9 (2002) 220-226
45. Sonntag K.C., Emery D.W., Yasumoto A., Haller G., Germana S., Sablinski T., Shimizu A., Yamada K., Shimada H., Arn S., Sachs D.H., and LeGuern C. Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest 107 (2001) 65-71
46. Bagley J., Tian C., Sachs D.H., and Iacomini J. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood 99 (2002) 4394-4399
47. Bagley J., Bracy J.L., Tian C., Kang E.S., and Iacomini J. Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci 7 (2002) 1331-1337
48. Karim M., Feng G., Wood K., and Bushell A. CD25+ CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen specific reactivation in vivo is critical for bystander regulation. Blood 105 (2005) 4871-4877
49. Lee M., Moore D., Jarrett B., Lian M.M., Deng S., Huang X., Markmann J.W., Chiaccio M., Barker C.F., Caton A.J., and Markmann J.F. Promotion of allograft survival by CD4+ CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J Immunol 172 (2004) 6539-6544
50. Ochando J., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., Angeli V., Li Y., Boros P., Ding Y., Jessberger R., Trinchieri G., Lira S.A., Randolph G.J., and Bromberg J.S. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7 (2006) 652-662
51. Chai J., Xue S., Coe D., Addey C., Bartok I., Scott D., Simpson E., Strauss H.J., Hori S., Sakaguchi S., and Dyson J. Regulatory T cells, derived from naive CD4+ CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 79 (2005) 1310-1316
52. Moore D., Markmann J., and Deng S. Avenues for immunomodulation and graft protection by gene therapy in transplantation. Transplant Int 19 (2006) 435-445
53. Waldmann H., Adams E., Fairchild P., and Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev 212 (2006) 301-313
54. Vassalli G., Gallino A., Weis M., von Scheidt W., Kappenberger L., von Segesser L.K., Goy J.J., and Working Group Microcirculation of the European Society of Cardiology. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24 (2003) 1180-1188
55. Bouche D., Chauveau C., Roussel J., Mathieu P., Braudeau C., Tesson L., Soulillou J.P., Iyer S., Buelow R., and Anegon I. Inhibition of graft arteriosclerosis development in rat aortas following heme oxygenase-1 gene transfer. Transplant Immunol 9 (2002) 235-238
56. Chauveau C., Bouchet D., Roussel J., Mathieu P., Braudeau C., Renaudin K., Tesson L., Soulillou J.P., Iyer S., Buelow R., and Anegon I. Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection. Am J Transplant 2 (2002) 581-592
57. Suzuki J., Isobe M., Morishita R., Nishikawa T., Amano J., and Kaneda Y. Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res 45 (2000) 783-787
58. Miniati D., Lijkwan M., Murata S., Martens J., Coleman C.T., Hoyt E.G., and Robbins R.C. Effects of adenoviral up-regulation of bcl-2 on oxidative stress and graft coronary artery disease in rat heart transplants. Transplantation 76 (2003) 382-386
59. Mathieu P., Guillot C., Gerdes C., Buzelin F., Lowenstein P., Castro M., Soulillou J.P., and Anegon I. Adenovirus-mediated CD40Ig expression attenuates chronic vascular rejection lesions in an aorta allotransplantation model. Transplant Proc 34 (2002) 743-744
60. Wang T., Dong C., Stevenson S., Herderick E.E., Marshall-Neff J., Vasudevan S.S., Moldovan N.I., Michler R.E., Movva N.R., and Goldschmidt-Clermont P.J. Overexpression of soluble fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation 106 (2002) 1536-1542
61. Sata M., Luo Z., and Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 166 (2001) 6964-6971
62. Saiura A., Sata M., Hiasa K., Kitamoto S., Washida M., Egashira K., Nagai R., and Makuuchi M. Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler Thromb Vasc Biol 24 (2004) 1886-1890
63. Dong C., Gong N., Chen Z., Chen X., Xu Q., Guo H., Zeng Z., Ming C., and Chen Z.K. Antisense ERK1/2 oligodeoxynucleotide gene therapy attenuates graft arteriosclerosis of aortic transplant in a rat model. Transplant Proc 38 (2006) 3304-3306
64. Feng Y., Jin Y., Zhang Q., Hao J., Wang G., and Xie S. CTLA4-Fas ligand gene transfer mediated by adenovirus induce long-time survival of murine cardiac allografts. Transplant Proc 37 (2005) 2379-2381
65. Scholl F., Sen L., Drinkwater D., Laks H., Ma X.Y., Hong Y.S., Chang P., and Cui G. Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant 20 (2001) 322-329
66. Tsukioka K., Suzuki J., Fujimori M., Wada Y., Yamaura K., Ito K., Morishita R., Kaneda Y., Isobe M., and Amano J. Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res 56 (2002) 472-478
67. Asif-Ullah M., Lévesque M., Robichaud G., and Perreault J.P. Development of ribozyme-based gene inactivations; the example of the hepatitis delta virus ribozyme. Curr Gene Ther 7 (2007) 205-216
68. Kawauchi M., Suzuki J., Morishita R., Wada Y., Izawa A., Tomita N., Amano J., Kaneda Y., Ogihara T., Takamoto S., and Isobe M. Gene therapy for attenuating cardiac allograft vasculopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 87 (2000) 1063-1068
69. Verma I.M. A voluntary moratorium?. Mol Ther 7 (2003) 141
70. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M., Wulffraat P.N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
71. Salama A.D., Remuzzi G., Harmon W.E., and Sayegh M.H. Challenges to achieving clinical transplantation tolerance. J Clin Invest 108 (2001) 943-948
72. Kay M.A., and Nakai H. Looking into the safety of AAV vectors. Nature 424 (2003) 251
73. Ye X., Rivera V.M., Zoltick P., Cerasoli Jr. F., Schnell M.A., Gao G., Hughes J.V., Gilman M., and Wilson J.M. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283 (1999) 88-91
74. McCurry K.R., Colvin B.L., Zahorchak A.F., and Thomson A.W. Regulatory dendritic cell therapy in organ transplantation. Transplant Int 19 (2006) 525-538
75. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., Cho H.R., Aruffo A., Hollenbaugh D., Linsley P.S., Winn K.J., and Pearson T.C. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438